Kumamoto University · Research Division of Life Sciences · 准教授

Research keywordslung adenocarcinoma・tumor immunology・PD-L1 expression・ferroptosis resistance・EGFR targeted therapy・interstitial lung disease・adjuvant chemotherapy・thoracic oncology

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Integrative analysis of T cell subset-specific ICOS expression and tumor HLA class I/II expression in lung adenocarcinoma: implications for their interaction and clinical outcome.2026 · Cancer immunology, immunotherapy : CII
• The expression of PD-1 ligands in the immune microenvironment was altered in TTF-1-negative lung adenocarcinoma.2025 · Human cell
• Hippo pathway controls biopterin metabolism to shield adjacent cells from ferroptosis in lung cancer.2025 · EMBO reports
• Phase 2 feasibility study of adjuvant chemotherapy with cisplatin (CDDP) and TS-1, followed by alternate-day TS-1 maintenance therapy, in patients with completely resected pathological stage II-IIIA non-small cell lung cancer.2025 · Journal of thoracic disease

• 非小細胞肺癌における腫瘍関連好中球浸潤の分子メカニズムとその臨床的意義の解明2022 · 科学研究費助成事業
• 非小細胞肺癌縮小手術におけるCDCA1-OSNA法の確立2020 · 科学研究費助成事業
• 非小細胞肺癌の発生、進行におけるERβとGPER1/GPR30の働きの解明2018 · 科学研究費助成事業 基盤研究(C)
• エストロジェン受容体発現量による予後・治療効果予測法の開発2017 · 科学研究費助成事業 基盤研究(C)

• Official profile